期刊
CELL
卷 134, 期 5, 页码 877-886出版社
CELL PRESS
DOI: 10.1016/j.cell.2008.07.041
关键词
-
资金
- National Institutes of Health
- Harvard Stem Cell Institute
- Children's Hospital Stem Cell Program
- John W. Henry Family Foundation
- Burroughs Wellcome Fund
- Leukemia and Lymphoma Society
- Natural Sciences and Engineering Council of Canada
- Sir James Lougheed Award
Tissue culture of immortal cell strains from diseased patients is an invaluable resource for medical research but is largely limited to tumor cell lines or transformed derivatives of native tissues. Here we describe the generation of induced pluripotent stem (iPS) cells from patients with a variety of genetic diseases with either Mendelian or complex inheritance; these diseases include adenosine deaminase deficiency-related severe combined immunodeficiency (ADA-SCID), Shwachman-Bodian-Diamond syndrome (SBDS), Gaucher disease (GD) type III, Duchenne (DMD) and Becker muscular dystrophy (BMD), Parkinson disease (PD), Huntington disease (HD), juvenile-onset, type 1 diabetes mellitus (JDM), Down syndrome (DS)/trisomy 21, and the carrier state of Lesch-Nyhan syndrome. Such disease-specific stem cells offer an unprecedented opportunity to recapitulate both normal and pathologic human tissue formation in vitro, thereby enabling disease investigation and drug development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据